Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Dose-Ranging Study in Patients With COPD

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00098228

Enrollment

686

Registered

2004-12-06

Start date

2004-07-31

Completion date

2004-12-31

Last updated

2011-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD, adults, QAB149

Brief summary

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Interventions

DRUGQAB149

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of COPD * Age 40-75 years * Smoking history

Exclusion criteria

* Other serious disease * Allergy to QAB149 * Respiratory tract infection

Design outcomes

Primary

Measure	Time frame
Pulmonary function measured between 22 and 24 hours after dosing on Day 1	—

Secondary

Measure	Time frame
Pulmonary function measured on days 1 and 7 at various intervals after dosing	—
Safety measurements	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026